论文部分内容阅读
旨探讨将单纯疱疹病毒Ⅰ型胸苷激酶基因载体生产细胞（pLTKcSN／VPC）脑内注射和腹腔注射更昔洛韦（GCV）在大鼠体内的急性系统性毒副作用，以及载体生产细胞（VPC）在大鼠脑内的存在时问。S-D大鼠24只，雌雄各半，随机分为2组。第1组颅内注射pLTKcSN／VPC，细胞总量3ｘ106/只，7天后腹腔注射GCV30mg·kg-1·d-1，共7天。GCV用药结束后1周处死动物，进行备脏器组织学检查及TK序列的聚合酶链反应（PCR）和原位杂交检测。第2组，采用脑内注射等量整合有β半乳糖苷酶基因（β-gal／nVPC），注射后的9、14、21和30天各处死3只动物，取注射针道周围脑组织行冰冻切片x-gal组化染色，观察VPC在大鼠脑内的生存时限。结果：第1组动物的各脏器组织学病理改变主要为脑内手术部位蛛网膜下腔出血、个别动物有心肌间质灶性炎症和肝细胞脂肪变性。TK序列聚合酶链反应（PCR）检测动物体内各脏器均未检出TK序列。x-gal组化染色见9天和21天两个时问点分别有1只动物脑内有阳性细胞存在。本文结果提示：pLTKcSN／VPC及GCV系统对大鼠脑及全身各脏器有轻微非特异性急性毒副作用，pLTKcSN／VPC在大鼠体内的生存时间约为3周。为pLTKCSN／VPC及GCV系统的临床试验治疗恶性脑胶质瘤提供了脑内注射PLTK。SN／VPC的安全性依据。
To investigate the acute and systemic side effects of intracerebroventricular injection of herpes simplex virus type 1 thymidine kinase gene vector (pLTKcSN / VPC) and intraperitoneal injection of ganciclovir (GCV) in rats and the effect of vector-producing cells (VPC ) In the rat brain when asked. Twenty-four S-D rats, male and female, were randomly divided into two groups. Group 1 received intracerebral injection of pLTKcSN / VPC with a total of 3 × 106 cells / day. GCV30 mg · kg -1 · d -1 was injected intraperitoneally 7 days later for 7 days. Animals were sacrificed one week after GCV administration, and histopathological examination of organ and polymerase chain reaction (PCR) of TK sequence and in situ hybridization were performed. In group 2, β-galactosidase gene (β-gal / nVPC) was homogeneously injected intracerebrally. Three animals were sacrificed at 9, 14, 21 and 30 days after injection, Frozen section x-gal staining, observe the VPC survival time in rat brain. Results: The histopathological changes of the organs in group 1 were mainly subarachnoid hemorrhage in the intracerebral operation site, and some animals had focal myocardial interstitial inflammation and hepatic steatosis. TK sequence polymerase chain reaction (PCR) detection of animals in vivo were not detected TK sequences. X-gal staining showed that there were 1 positive cells in the brain at 9 days and 21 days respectively. Our results suggest that pLTKcSN / VPC and GCV systems have mild and non-specific acute side effects on rat brain and systemic organs. The survival time of pLTKcSN / VPC in rats is about 3 weeks. An intracerebral injection of PLTK was provided for the treatment of malignant gliomas in clinical trials of the pLTKCSN / VPC and GCV systems. SN / VPC security basis.